Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study

Harris, Steven T.; Reginster, Jean‐Yves; Harley, Carolyn; Blumentals, William A.; Poston, Sara; Barr, Charles; Silverman, Stuart L.

doi:10.1016/j.bone.2009.01.002

Cited by 59 publications

(59 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vertebral and non-vertebral fractures are major factors that affect patient's QoL. The recent head-to-head database fracture study demonstrated significantly lower relative risk of vertebral fracture in patients receiving ibandronate than weekly bisphosphonates (22). However, the present study was not designed to asses the number and location of vertebral fractures either at baseline or at the end of the study.…”

Section: Resultsmentioning

confidence: 81%

Health-Related Quality of Life Among Patients with Postmenopausal Osteoporosis Treated with Weekly and Monthly Bisphosphonates

Kaštelan¹,

Vlak²,

Lozo³

et al. 2010

Endocrine Research

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 81%

Health-Related Quality of Life Among Patients with Postmenopausal Osteoporosis Treated with Weekly and Monthly Bisphosphonates

Kaštelan¹,

Vlak²,

Lozo³

et al. 2010

Endocrine Research

View full text Add to dashboard Cite

show abstract

“…15 Previous observational studies have looked at fracture risk. Harris et al (2009) found that rates of hip, nonvertebral, or any clinical fracture rate did not significantly differ between monthly ibandronate and weekly alendronate or risedronate in adherent (no discontinuation of bisphosphonate within 90 days of index date) women aged 45 years or older receiving up to 1 year of treatment; however, rates of vertebral facture were lower with ibandronate. 11 Weekly risedronate was associated with lower rates of hip and nonvertebral fractures than weekly alendronate in women aged 65 years or older in the first year following treatment in an analysis by Silverman et al (2007).…”

Section: Limitationsmentioning

confidence: 92%

“…Several observational studies have recently been published for the bisphosphonates; however, differences in study populations, methodology, and outcomes measured make it difficult to compare the effectiveness of the medications and claims of superiority of one drug over another. [10][11][12][13][14][15][16] For health plans and other decision makers, having a complete picture of how the medication is actually used and the resulting outcomes may prove useful and increase the likelihood of making the most appropriate coverage decisions. Given the lack of headto-head RCTs and the limitations of published observational studies of oral bisphosphonates, a health plan-sponsored retrospective analysis of administrative claims was designed to determine if there were differences among oral bisphosphonate agents in their effectiveness as measured by adherence, fracture rates, or total cost of care in a large managed care population.…”

Section: What Is Already Known About This Subjectmentioning

confidence: 99%

Analysis of the Comparative Effectiveness of 3 Oral Bisphosphonates in a Large Managed Care Organization: Adherence, Fracture Rates, and All-Cause Cost

Martin

Yu²,

Campbell³

et al. 2011

JMCP

View full text Add to dashboard Cite

• Randomized, controlled trials (RCTs) of oral bisphosphonates have shown statistically significant reductions in fracture rates versus placebo, but whereas alendronate and risedronate have shown reductions in vertebral and nonvertebral fractures, ibandronate has been shown to reduce vertebral fractures only. Comparison of fracture rates among the bisphosphonates is difficult due to the lack of head-to-head RCTs designed to compare this outcome.• Several observational studies regarding osteoporosis therapy have been published. A recent analysis by Halpern et al. (2011) showed that low adherence (medication possession ratio [MPR] < 80%) was associated with 37% higher fracture risks and 12% higher all-cause medical costs. However, there is a lack of comparative effectiveness data for adherence, fracture rates, and total cost of care among the 3 commonly used oral bisphosphonates (alendronate, risedronate, and ibandronate) for a period longer than 12-18 months. What is already known about this subject

show abstract

“…Indeed, the risk of any fracture is significantly lower in patients prescribed monthly ibandronate than weekly bisphosphonate (adjusted relative risk=0.65, p=0.033). 29 Intravenous bisphosphonates are more bioavailable than oral bisphosphonates. A higher ibandronate dose (annual cumulative exposure ≥10.8 mg) significantly reduces the risk of non-vertebral fracture in postmenopausal women.…”

Section: Discussionmentioning

confidence: 99%

Combined Use of Ibandronate and Eldecalcitol in Postmenopausal Japanese Women with Osteoporosis

Takada

Wada²,

Iba

et al. 2016

J Orthop Surg (Hong Kong)

View full text Add to dashboard Cite

Purpose.To evaluate the effect of combined use of ibandronate and eldecalcitol for 6 to 12 months on bone mineral density (BMD) and bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis. Methods. BMD and bone strength of the proximal femur were evaluated in 78 postmenopausal women (mean age, 73.6 years) who underwent treatment for osteoporosis with combined use of ibandronate and eldecalcitol for at least 6 months. BMD was measured at the lumbar spine, femoral neck, and total hip using dual-energy X-ray absorptiometry (DXA) at baseline and every 6 months thereafter. Hip structure analysis of the narrow neck and intertrochanter was performed by a radiologist using DXA images. Results. Respectively for the lumbar spine, femoral neck, and total hip, BMD significantly increased (from baseline) by 4.54%, 2.31%, and 1.56% at 6 months and by 5.92%, 3.02%, and 2.70% at 12 months. In hip structure analysis, most parameters improved significantly. Respectively for the narrow neck and intertrochanter, BMD significantly increased (from baseline) by 2.37% and 2.71% at 6 months and by 3.46% and 3.52% at 12 months; cross-sectional area significantly increased by 1.83% and 3.39% at 6 months and by 2.91% and 3.46% at 12 months; section modulus significantly increased by 2.42% and 4.11% at 6 months and by 4.84% and 3.26% at 12 months; cortical thickness significantly increased by 2.49% and 3.33% at 6 months and by 3.73% and 3.37% at 12 months; and buckling ratio significantly decreased by 2.97% and 2.57% at 6 months and by 3.86% and 2.99% at 12 months. Conclusion. Combined use of ibandronate and eldecalcitol for 6 months significantly improved bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.

show abstract

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study

Cited by 59 publications

References 27 publications

Health-Related Quality of Life Among Patients with Postmenopausal Osteoporosis Treated with Weekly and Monthly Bisphosphonates

Health-Related Quality of Life Among Patients with Postmenopausal Osteoporosis Treated with Weekly and Monthly Bisphosphonates

Analysis of the Comparative Effectiveness of 3 Oral Bisphosphonates in a Large Managed Care Organization: Adherence, Fracture Rates, and All-Cause Cost

Combined Use of Ibandronate and Eldecalcitol in Postmenopausal Japanese Women with Osteoporosis

Contact Info

Product

Resources

About